Drug Profile
Research programme: Bcl-2 inhibitors - Infinity/Novartis
Alternative Names: Bcl-2 inhibitors - Infinity/NovartisLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Infinity Pharmaceuticals
- Developer Novartis
- Class Small molecules
- Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Cancer in USA
- 30 Apr 2012 Early research is ongoing in USA
- 06 Mar 2006 Early research in Cancer in USA (unspecified route)